Item 8.01 Other Events.

On January 22, 2023, Pliant Therapeutics, Inc. (the "Company") announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis ("IPF"). The 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile. The trial's exploratory efficacy endpoints assessed changes in forced vital capacity ("FVC"), Quantitative Lung Fibrosis ("QLF") imaging and biomarkers. Bexotegrast at 320 mg demonstrated a statistically significant mean increase in FVC from baseline at all timepoints, surpassing all lower dose cohorts, and showed a strong treatment effect on FVC percent predicted, QLF and profibrotic biomarkers versus placebo at 12 weeks. A copy of the Company's press release, titled "Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis," is attached as Exhibit 99.1 to this Current Report and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.                                    Description

99.1          Press Release, dated January 22, 2023, titled "Pliant Therapeutics
            Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial
            Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved
            Statistically Significant FVC Increase in Patients with Idiopathic
            Pulmonary Fibrosis."

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses